Dihydroartemisinin inhibits endothelial cell migration via the TGF-β1/ALK5/SMAD2 signaling pathway.
TGF-β1/ALK5/SMAD2 pathway
angiogenesis
dihydroartemisinin
endothelial cell migration
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
01
09
2020
accepted:
12
03
2021
entrez:
19
5
2021
pubmed:
20
5
2021
medline:
20
5
2021
Statut:
ppublish
Résumé
Anti-angiogenesis therapy is a novel treatment method for malignant tumors. Endothelial cell (EC) migration is an important part of angiogenesis. Dihydroartemisinin (DHA) exhibits strong anti-angiogenic and anti-EC migration effects; however, the underlying molecular mechanisms are yet to be elucidated. The TGF-β1/activin receptor-like kinase 5 (ALK5)/SMAD2 signaling pathway serves an important role in the regulation of migration. The present study aimed to explore the effects of DHA treatment on EC migration and the TGF-β1/ALK5/SMAD2 signaling pathway. The effects of DHA on human umbilical vein EC migration were assessed using wound healing and Transwell assays. The effects of DHA on the TGF-β1/ALK5/SMAD2 signaling pathway were detected using western blotting. DHA exhibited an inhibitory effect on EC migration in the wound healing and Transwell assays. DHA treatment upregulated the expression levels of ALK5 and increased the phosphorylation of SMAD2 in ECs. SB431542 rescued the inhibitory effect of DHA during EC migration. DHA inhibited EC migration via the TGF-β1/ALK5/SMAD2-dependent signaling pathway, and DHA may be a novel drug for the treatment of patients with malignant tumors.
Identifiants
pubmed: 34007318
doi: 10.3892/etm.2021.10141
pii: ETM-0-0-10141
pmc: PMC8120513
doi:
Types de publication
Journal Article
Langues
eng
Pagination
709Informations de copyright
Copyright: © Guo et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Surgery. 1981 Aug;90(2):262-70
pubmed: 6166996
Angiogenesis. 2004;7(4):313-21
pubmed: 15886875
Int J Biochem Cell Biol. 2018 Dec;105:52-60
pubmed: 30120989
Cancer Biol Ther. 2014;15(11):1479-88
pubmed: 25482945
PLoS One. 2012;7(11):e50351
pubmed: 23209720
J Cell Sci. 2007 Apr 1;120(Pt 7):1256-66
pubmed: 17376964
Cell. 1998 Dec 11;95(6):737-40
pubmed: 9865691
Mol Cell. 2003 Oct;12(4):817-28
pubmed: 14580334
Endokrynol Pol. 2013;64(5):384-96
pubmed: 24186596
J Cell Sci. 2009 Sep 15;122(Pt 18):3294-302
pubmed: 19706683
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Life Sci. 2020 Feb 1;242:117221
pubmed: 31881224
Nat Med. 2000 Apr;6(4):389-95
pubmed: 10742145
Cancer Chemother Pharmacol. 2004 May;53(5):423-32
pubmed: 15132130
FASEB J. 1992 Feb 1;6(3):886-92
pubmed: 1371260
J Biomed Biotechnol. 2012;2012:247597
pubmed: 22174561
Int Immunopharmacol. 2013 Jun;16(2):306-12
pubmed: 23583335
J Adv Res. 2017 Nov;8(6):591-605
pubmed: 28808589
EMBO J. 2002 Apr 2;21(7):1743-53
pubmed: 11927558
Theranostics. 2018 Nov 26;8(21):6053-6069
pubmed: 30613282
Chem Biol. 1999 Aug;6(8):R217-24
pubmed: 10421764
Wiad Lek. 2005;58(9-10):536-9
pubmed: 16529065
Int J Mol Med. 2017 Oct;40(4):972-978
pubmed: 28765885
Trends Cardiovasc Med. 2003 Oct;13(7):301-7
pubmed: 14522471
J Photochem Photobiol B. 2020 Aug;209:111924
pubmed: 32570058
Curr Biol. 2003 Sep 30;13(19):R756-9
pubmed: 14521851
Circ Res. 2007 Mar 30;100(6):782-94
pubmed: 17395884
Am J Pathol. 1993 Aug;143(2):401-9
pubmed: 7688183
Mol Cancer Ther. 2016 Apr;15(4):702-10
pubmed: 26809491
Cytokine Growth Factor Rev. 1997 Mar;8(1):21-43
pubmed: 9174661
Exp Ther Med. 2014 Dec;8(6):1707-1712
pubmed: 25371719
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):211-7
pubmed: 12588761
Trends Cell Biol. 2004 Mar;14(3):107-11
pubmed: 15055198
Exp Cell Res. 2001 Feb 1;263(1):173-82
pubmed: 11161716
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31
pubmed: 10716993